Skip to Main Content

++

INTRODUCTION

++

febuxostat (fe-bux-oh-stat)

Uloric

Classification

Therapeutic: antigout agents

Pharmacologic: xanthine oxidase inhibitors

++
Indications
++

Chronic management of hyperuricemia in patients with a history of gout.

++
Action
++

Decreases production of uric acid by inhibiting xanthine oxidase. Therapeutic Effects: Lowering of serum uric acid levels with resultant decrease in gouty attacks.

++
Adverse Reactions/Side Effects
++

GI: liver function abnormalities, nausea. Derm: rash. MS: gout flare, arthralgia.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Be alert for signs of abnormal liver function, including anorexia, abdominal pain, severe nausea and vomiting, yellow skin or eyes, fever, sore throat, malaise, weakness, facial edema, lethargy, and unusual bleeding or bruising. Notify physician of these signs immediately.

  • Assess joints affected by gout, and monitor pain and other variables (range of motion, muscle strength) to document whether this drug is successful in helping manage the patient's gout. Report any increased pain in joints (arthralgia) or gout flare-ups that might be related to drug treatment.

++
Interventions
++

  • Implement appropriate manual therapy techniques, physical agents, and therapeutic exercises to decrease pain and help reduce the frequency and severity of gout attacks.

++
Patient/Client-Related Instruction
++

  • Instruct patient and family/caregivers about the signs of liver toxicity (see above in Examination and Evaluation). Encourage early recognition and notification of the physician or other health care professional about these signs.

  • Instruct patient and family/caregivers to report severe or prolonged nausea or skin rash.

++
Pharmacokinetics
++

Absorption: Well absorbed (49%) following oral administration.

++

Distribution: Unknown.

++

Protein Binding: 99.2%.

++

Metabolism and Excretion: Extensively metabolized by the liver; minimal renal excretion of unchanged drug; 45% eliminated in feces as unchanged drug, remainder is eliminated in urine and feces as inactive metabolites.

++

Half-life: 5–8 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (blood levels)

ROUTE ONSET PEAK DURATION
PO rapid 1–1.5 hr* 24 hr

*Maximum lowering of uric acid may take 2 wk.

++
Contraindications/Precautions
++

Contraindicated in: Concurrent azathioprine, mercaptopurine, or theophylline.

++

Use Cautiously in: Severe renal impairment (CCr <30 mL/min); Severe hepatic impairment; OB: Use in pregnancy only when potential maternal benefit outweighs potential fetal risk; Pedi: Safety in children <18 yr not established.

++
Interactions
++

Drug-Drug: Significantly ↑ blood levels of, and risk of serious toxicity from, azathioprine, mercaptopurine, and theophylline; concurrent use is contraindicated.

++
Route/Dosage
++

PO (Adults): 40 mg once daily initially; if serum uric acid does not drop to <6 mg/dL, dose should be increased to 80 mg daily.

++
Availability
++

Tablets: 40 mg, 80 mg.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.